Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Avosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB | P24530 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avosentan SCHEMBL29379732 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Avosentan SCHEMBL13391096 | 0.95 | EDNRA (0.91) | EDNRAEDNRB | |
| Avosentan SCHEMBL13391134 | 0.95 | EDNRA (0.91) | EDNRAEDNRB | |
| SCHEMBL14387345 | 0.94 | EDNRA (0.88) | EDNRAEDNRB | |
| Avosentan SCHEMBL13391106 | 0.93 | EDNRA (0.86) | EDNRAEDNRB | |
| SCHEMBL13391059 | 0.92 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL25637066 | 0.91 | EDNRA (0.84) | EDNRAEDNRB | |
| SCHEMBL2669624 | 0.91 | EDNRA (0.84) | EDNRAEDNRB | |
| SCHEMBL7194130 | 0.91 | EDNRA (0.82) | EDNRAEDNRB | |
| SCHEMBL6786069 | 0.90 | EDNRA (0.82) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | SPEEDEL PHARMA AG (CH) | 2010-06-24 | — | — | US | claimed |
| EP-1601361-B1 | PYRIDYLSULFONAMIDO PYRIMIDINES FOR TREATING DIABETIC NEPHROPATHY | SPEEDEL PHARMA AG (CH) | 2008-05-14 | — | — | EP | claimed |
| EP-1185525-B1 | 4-HETEROCYCLYLSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | claimed |
| US-20060094731-A1 | New medicament | SPEEDEL PHARMA AG (CH) | 2006-05-04 | — | — | US | claimed |
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| EP-2683698-B1 | BENZYL-OXATHIAZINE DERIVATES SUBSTITUTED WITH ADAMANTANE OR NORADAMANTANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI SA (FR) | 2017-10-04 | — | — | EP | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | disclosed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| EP-2203416-B1 | (CARBOXY ALKYLENE-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2144885-B1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2016-06-29 | — | — | EP | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039174-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039176-A1 | DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20060094731-A1 | New medicament | SPEEDEL PHARMA AG (CH) | 2006-05-04 | — | — | US | disclosed |
| WO-2005113543-A1 | CRYSTALLINE FORMS OF A PYRIDINYL-SULFONAMIDE AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | SPEEDEL PHARMA AG (CH) | 2005-12-01 | — | — | WO | disclosed |
| US-6521631-B2 | N-(6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4 -yl)) 5-isopropyl-pyridine-2-sulfonamide; treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction. | HOFFMANN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094731-A1 | New medicament | REN, SLC5A1, GLS | EDNRA 164/4885EDNRB 279/4885 |
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | PDXK, CBS, C1S | EDNRA 395/4885EDNRB 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.